Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats

被引:25
作者
Karzai, W
Cui, XZ
Mehlhorn, B
Straube, E
Hartung, T
Gerstenberger, E
Banks, SM
Natanson, C
Reinhart, K
Eichacker, PQ
机构
[1] Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Germany
[2] Univ Hosp, Dept Microbiol, Jena, Germany
关键词
D O I
10.1097/00000542-200307000-00016
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Differing factors may alter the effects of antibody to tumor necrosis factor (TNF) in infection and sepsis. The authors tested whether bacteria type or treatment route alters antibody to TNF in a rat model of bacterial pneumonia. Methods: Rats (n = 231) received similarly lethal doses of either intratracheal Escherichia coli or Staphylococcus aureus followed by treatment with either intratracheal or intraperitoneal antibody to TNF or control serum. Animals received antibiotics (cefotiam daily dose, 100 mg/kg) starting 4 h after inoculation and were studied for up to 96 h. Results: Compared with S. aureus, E coli increased serum TNF and interleukin-6 concentrations, lung lavage TNF concentrations, neutrophil counts, and alveolar-to-arterial oxygen gradients and decreased circulating nentrophils and lymphocytes (P greater than or equal to 0.05 for all). Compared with controls, with both bacteria, except for lung lavage TNF concentrations (which decreased with intratracheal but not with intraperitoneal antibody to TNF), treatment route did not alter the effects of antibody to TNF on any parameter (P = not significant for all). Antibody to TNF reduced mortality rates (relative risk of death +/- SEM) with both E. coli (-1.6 +/- 0.6; P = 0.006) and S. aureus (-0.5 +/- 0.04; P = 0.185), but these reductions were greater with E. coli than with S. aureus in a trend approaching statistical significance (P = 0.09). Compared with controls, similarly (P = not significant) with both bacteria, antibody to TNF decreased lung lavage and tissue bacteria concentrations (both P < 0.05) and serum TNF concentration (P < 0.09) and increased circulating neutrophils and lymphocytes (both P less than or equal to 0.01). Compared with S. aureus, with E. coli antibody to TNF decreased alveolar-to-arterial oxygen gradients (P = 0.04) and increased serum interleukin-6 concentrations (P = 0.003). Conclusion: Antibody to TNF improved host defense and survival rates with both lethal E. coli and S. aureus pneumonia, but protection was greater with E. coli, where TNF concentrations were higher than with S. aureus. The efficacy of antiinflammatory agents in sepsis may be altered by bacteria type.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 62 条
  • [11] INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
    Cohen, J
    Carlet, J
    [J]. CRITICAL CARE MEDICINE, 1996, 24 (09) : 1431 - 1440
  • [12] THE EFFICACY OF COMBINATION IMMUNOTHERAPY IN EXPERIMENTAL PSEUDOMONAS SEPSIS
    CROSS, AS
    OPAL, SM
    PALARDY, JE
    BODMER, MW
    SADOFF, JC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (01) : 112 - 118
  • [13] Differential tumor necrosis factor alpha expression and release from peritoneal mouse macrophages in vitro in response to proliferating cram-positive versus gram-negative bacteria
    Cui, W
    Morrison, DC
    Silverstein, R
    [J]. INFECTION AND IMMUNITY, 2000, 68 (08) : 4422 - 4429
  • [14] CDP571, A HUMANIZED ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA - SAFETY, PHARMACOKINETICS, IMMUNE-RESPONSE, AND INFLUENCE OF THE ANTIBODY ON CYTOKINE CONCENTRATIONS IN PATIENTS WITH SEPTIC SHOCK
    DHAINAUT, JFA
    VINCENT, JL
    RICHARD, C
    LEJEUNE, P
    MARTIN, C
    FIEROBE, L
    STEPHENS, S
    NEY, UM
    SOPWITH, M
    MERCAT, A
    EDOUARD, A
    FRIEDMAN, G
    MARIN, N
    SCHLEMMER, B
    LEPAPE, A
    NOVAK, C
    [J]. CRITICAL CARE MEDICINE, 1995, 23 (09) : 1461 - 1469
  • [15] ECHTENACHER B, 1990, J IMMUNOL, V145, P3762
  • [16] Risk and the efficacy of antiinflammatory agents - Retrospective and confirmatory studies of sepsis
    Eichacker, PQ
    Parent, C
    Kalil, A
    Esposito, C
    Cui, X
    Banks, SM
    Gerstenberger, EP
    Fitz, Y
    Danner, RL
    Natanson, C
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (09) : 1197 - 1205
  • [17] ESKANDARI MK, 1992, J IMMUNOL, V148, P2724
  • [18] A HIGHLY SENSITIVE CELL-LINE, WEHI-164 CLONE 13, FOR MEASURING CYTOTOXIC FACTOR TUMOR-NECROSIS-FACTOR FROM HUMAN-MONOCYTES
    ESPEVIK, T
    NISSENMEYER, J
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (01) : 99 - 105
  • [19] PROTECTIVE EFFECT OF 55-KD BUT NOT 75-KD SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR IMMUNOGLOBULIN-G FUSION PROTEINS IN AN ANIMAL-MODEL OF GRAM-NEGATIVE SEPSIS
    EVANS, TJ
    MOYES, D
    CARPENTER, A
    MARTIN, R
    LOETSCHER, H
    LESSLAUER, W
    COHEN, J
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (06) : 2173 - 2179
  • [20] FIEDLER VB, 1992, J LAB CLIN MED, V120, P574